On 9 May 2024, Rani Therapeutics announced that it will present pre-clinical and clinical data at Digestive Disease Week in the US (18-21 May 2024) regarding RT-111, an oral delivery platform known as the RaniPill® capsule, containing Celltrion’s ustekinumab biosimilar, CT-P43 (biosimilar to Janssen’s Stelara®). The title of one of the abstracts to be presented suggests that the RaniPill® was found to reliably and safely deliver ustekinumab with high bioavailability relative to subcutaneous ustekinumab in healthy human participants.
On 5 February 2024, Rani Therapeutics published positive topline results from a phase 1 clinical trial of RT-111. In June 2023, Rani expanded its partnership with Celltrion to develop an orally administered adalimumab biosimilar (RT-105), in addition to RT-111.